Amicus Therapeutics, Inc.
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
About
CEO
Mr. Bradley L. Campbell M.B.A.
Employees
500
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
47 Hulfish Street, Princeton, NJ 08542, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 4, 2025 | — | — | — | — |
| Aug 6, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Feb 26, 2025 | 0.02 | — | — | — |
| Nov 6, 2024 | — | -0.02 | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 3 | — | 6 |
| Average estimate | — | 0.06 | — | 0.38 |
| Low estimate | — | 0.02 | — | 0.14 |
| High estimate | — | 0.08 | — | 0.60 |
| Last year EPS | — | -0.02 | — | 0.23 |
[stock_revenue_estimate]
Growth estimates
Current qtr
794.700%
Next qtr. (Mar 2025)
383.350%
Current year
279.740%
Next year (Dec 2025)
62.700%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M |
| Cost of revenue | 37.33M | 38.60M | 34.47M | 31.04M | 21.96M |
| Gross profit | 362.03M | 290.63M | 271.05M | 229.84M | 160.27M |
| Operating expense | |||||
| Research & development | 152.38M | 276.68M | 272.05M | 308.44M | 286.38M |
| Selling general and admin | 275.27M | 213.04M | 192.71M | 156.41M | 169.86M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -73.49M | -204.43M | -199.92M | -243.85M | -300.74M |
| Non operating interest income | |||||
| Income | 7.08M | 3.02M | 509,000 | 3.23M | 10.25M |
| Expense | 50.15M | 37.12M | 32.47M | 22.43M | 18.87M |
| Other income expense | -33.54M | -3.52M | -9.67M | -11.20M | -46.55M |
| Pretax income | -150.10M | -242.04M | -241.55M | -274.25M | -355.91M |
| Tax provision | 1.48M | -5.47M | 8.91M | 2.60M | 478,000 |
| Net income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M |
| Basic EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 |
| Diluted EPS | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 |
| Basic average shares | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M |
| Diluted average shares | 295.16M | 289.06M | 271.42M | 258.87M | 240.42M |
| EBITDA | -74.43M | -191.88M | -196.10M | -232.56M | -328.97M |
| Net income from continuing op. | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 777.88M | 724.17M | 905.14M | 886.52M | 850.21M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 246.99M | 148.81M | 245.20M | 163.24M | 142.84M |
| Other short term investments | 39.21M | 144.78M | 237.30M | 320.03M | 309.90M |
| Accounts receivable | 87.63M | 66.20M | 52.67M | 46.92M | 33.28M |
| Other receivables | — | — | — | — | — |
| Inventory | 59.70M | 23.82M | 26.82M | 19.56M | 14.04M |
| Prepaid assets | — | — | 34.85M | 29.72M | 20.01M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 49.53M | 40.21M | 34.85M | 29.72M | 20.01M |
| Non current assets | |||||
| Properties | 42.53M | 45.88M | 37.25M | 38.68M | 53.23M |
| Land and improvements | — | — | 3.19M | 3.19M | 3.19M |
| Machinery furniture equipment | 9.03M | 8.39M | 10.13M | 9.76M | 13.07M |
| Construction in progress | 3.81M | 4.16M | 8.23M | 5.87M | 4.18M |
| Leases | 28.03M | 24.16M | 24.17M | 24.15M | 30.29M |
| Accumulated depreciation | -25.43M | -22.28M | -19.88M | -14.49M | -22.95M |
| Goodwill | 416.08M | 418.59M | 418.59M | 418.59M | 418.59M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 20.49M | 23.00M | 23.00M | 23.00M | 23.00M |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 18.55M | 19.24M | 24.43M | 19.10M | 28.32M |
| Total liabilities | 617.71M | 601.12M | 597.77M | 600.14M | 373.78M |
| Current liabilities | |||||
| Accounts payable | 15.12M | 15.41M | 21.51M | 17.06M | 21.72M |
| Accrued expenses | 83.14M | 54.53M | 59.02M | 52.00M | 56.23M |
| Short term debt | 8.32M | 8.55M | 7.41M | 6.87M | 7.19M |
| Deferred revenue | — | — | — | 1.50M | 1.25M |
| Tax payable | 12.43M | 5.94M | 6.15M | 11.18M | 7.30M |
| Pensions | 38.31M | 25.70M | 24.26M | 23.03M | 27.16M |
| Other current liabilities | 10.37M | 7.47M | 4.20M | 4.09M | 2.77M |
| Non current liabilities | |||||
| Long term debt | 436.74M | 443.57M | 432.72M | 434.86M | 203.04M |
| Provision for risks and charges | — | — | 1.44M | 16.93M | 22.68M |
| Deferred liabilities | — | 4.94M | 4.93M | 4.90M | 5.05M |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 13.28M | 18.53M | 8.24M | 6.38M | 5.30M |
| Shareholders equity | |||||
| Common stock | 2.92M | 2.82M | 2.81M | 2.65M | 2.60M |
| Retained earnings | -2.68B | -2.53B | -2.30B | -2.05B | -1.77B |
| Other shareholders equity | 5.24M | -12.11M | 4.98M | 8.23M | 2.83M |
| Total shareholders equity | 160.17M | 123.05M | 307.37M | 286.38M | 476.43M |
| Additional paid in capital | 2.84B | 2.66B | 2.60B | 2.31B | 2.23B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||
| Net Income | -151.58M | -236.57M | -250.46M | -276.85M | -356.39M | -349.00M | -284.00M | -200.04M | -132.12M | -68.93M | -59.63M | -48.79M | -44.41M | -54.94M | -6.57M | -39.36M | -41.17M | -46.35M | -19.97M |
| Depreciation | 7.87M | 5.34M | 6.21M | 8.85M | 4.78M | 4.22M | 3.59M | 3.24M | 1.83M | 1.55M | 1.72M | 1.71M | 1.59M | 2.06M | 2.13M | 1.49M | 1.24M | 952,000 | 667,383 |
| Deferred Taxes | -4.94M | 9,000 | 34,000 | -155,000 | -1.42M | — | -167.31M | -3.74M | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 86.08M | 76.51M | 57.84M | 49.15M | 44.43M | 29.26M | 23.10M | 17.50M | 9.97M | 6.01M | 6.18M | 6.19M | 8.68M | 6.19M | 7.79M | 6.45M | — | — | — |
| Other Non-Cash Items | -16.15M | 3.71M | -1.35M | 4.94M | 46.32M | 14.34M | -224.63M | 14.13M | 4.88M | 314,000 | 1.99M | — | -2.76M | 1.41M | — | 6.45M | 4.13M | 4.53M | 391,945 |
| Accounts Receivable | -20.11M | -17.33M | -8.19M | -11.22M | -11.11M | -13.29M | -7.73M | -1.42M | — | 1.08M | 2.14M | 1.82M | -5.04M | — | — | — | — | — | — |
| Accounts Payable | 49.20M | -6.38M | 7.43M | -10.61M | 46.74M | 17.12M | 12.56M | 7.13M | 15.47M | 6.17M | -613,000 | -863,000 | 1.42M | -1.35M | — | — | — | — | — |
| Other Assets & Liabilities | -47.67M | -9.98M | -11.91M | -1.47M | -20.73M | -11.04M | -13.51M | -3.80M | -1.44M | -157,000 | 6.26M | 3.18M | -5.22M | 32.50M | -47.96M | -5.75M | 50.61M | 264,000 | -491,202 |
| Operating Cash Flow | -97.30M | -184.68M | -200.39M | -237.37M | -247.38M | -308.40M | -657.91M | -167.00M | -101.40M | -53.96M | -41.96M | -36.75M | -45.76M | -14.13M | -44.61M | -30.72M | 14.82M | -40.60M | -19.40M |
| Investing Activities | |||||||||||||||||||
| Capital Expenditures | — | — | — | — | — | — | -4.53M | -5.95M | -4.82M | -238,000 | -695,000 | -4.32M | -1.42M | -384,000 | -1.81M | -2.67M | -669,000 | -2.03M | -3.04M |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | -141.06M | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -91.72M | -243.26M | -341.40M | -365.18M | -383.88M | -578.39M | -490.47M | -219.93M | -289.60M | -162.75M | -56.56M | -118.46M | -50.60M | -113.66M | -98.17M | -153.69M | -200.74M | -62.01M | -16.99M |
| Sale of Investments | 197.23M | 335.93M | 424.04M | 354.83M | 499.05M | 463.50M | 323.75M | 221.37M | 290.13M | 55.91M | 83.34M | 83.35M | 98.47M | 94.60M | 131.85M | 178.10M | 126.37M | 37.44M | 3.09M |
| Investing Cash Flow | 105.50M | 96.08M | 82.65M | -10.35M | 115.17M | -114.89M | -171.24M | -4.51M | -145.34M | -107.08M | 26.08M | -39.43M | 46.45M | -19.44M | 31.87M | 21.75M | -75.04M | -26.60M | -16.94M |
| Financing Activities | |||||||||||||||||||
| Long-Term Debt Issuance | 387.36M | — | — | 385.93M | — | 146.60M | — | 272.54M | 50.00M | — | 14.89M | 995,000 | — | — | 3.76M | — | — | — | — |
| Long-Term Debt Payments | -408.32M | -283,000 | -479,000 | -155.33M | -420,000 | -334,000 | -308,000 | -80.19M | -15.29M | -299,000 | -398,000 | -1.34M | -1.29M | -1.57M | -1.05M | -1.53M | — | — | — |
| Other Financing Charges | -20.57M | -11.49M | -16.66M | -10.03M | 16.64M | -2.83M | -11.60M | -19.73M | -2.04M | — | -110,000 | — | — | — | — | — | 546,000 | 3.43M | 1.11M |
| Financing Cash Flow | 51.40M | -11.77M | 182.62M | 220.58M | 205.21M | 438.01M | 231.13M | 269.68M | 275.71M | 135.51M | 29.38M | 79.85M | -1.29M | 43.65M | 1.87M | -3.06M | 93.30M | 67.05M | 41.53M |
| Other Cash Details | |||||||||||||||||||
| End Cash Position | 250.08M | 153.12M | 249.46M | 166.16M | 146.34M | 82.38M | 51.24M | 187.41M | 69.49M | 24.07M | 43.64M | 33.97M | 25.67M | 29.57M | 19.34M | 28.07M | 44.19M | 12.13M | 6.45M |
| Income Tax Paid | 8.53M | 1.07M | 20.03M | 10.37M | 691,000 | 1.06M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 36.09M | 34.36M | 30.47M | 24.68M | 16.97M | 7.50M | 7.42M | 2.99M | 605,000 | 1.19M | 30,000 | 84,000 | 149,000 | 280,000 | 250,000 | 218,000 | — | — | — |
| Free Cash Flow | -76.53M | -170.34M | -206.38M | -236.52M | -270.43M | -306.26M | -218.22M | -156.10M | -104.96M | -51.91M | -46.49M | -38.07M | -50.84M | -14.37M | -45.18M | -39.53M | 14.52M | -35.92M | -21.16M |
Error: Invalid format in Holders JSON file.
Article
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.
Feb 10, 2025
Article
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA.
Feb 3, 2025
Article
NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases
Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra
Jan 23, 2025
